TY  - JOUR
AU  - Byrom, Bill
AU  - Everhart, Anthony
AU  - Cordero, Paul
AU  - Garratt, Chris
AU  - Meyer, Tim
PY  - 2025
DA  - 2025/2/28
TI  - Leveraging Patient-Reported Outcome Measures for Optimal Dose Selection in Early Phase Cancer Trials
JO  - JMIR Cancer
SP  - e64611
VL  - 11
KW  - clinical trials
KW  - early phase
KW  - dose finding
KW  - patient-reported outcome
KW  - PRO
KW  - electronic patient-reported outcome
KW  - ePRO
KW  - PRO-CTCAE
KW  - adverse events
KW  - tolerability
KW  - optimal dose
KW  - cancer trials
KW  - dose toxicity
KW  - oncology
KW  - drug development
KW  - electronic collection
KW  - dose level
KW  - pharmacodynamic
KW  - cytotoxic chemotherapy drugs
KW  - cytotoxic
KW  - chemotherapy drug
KW  - life-threatening disease
KW  - Common Terminology Criteria for Adverse Events
SN  - 2369-1999
UR  - https://cancer.jmir.org/2025/1/e64611
UR  - https://doi.org/10.2196/64611
DO  - 10.2196/64611
ID  - info:doi/10.2196/64611
ER  -